Total Funding
21
31
Total FundingSeed raised
Growth Score
-5 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
95329
Betaliq is a biotech company that focuses on the development of ophthalmic beta-blockers.
Barry Butler: CEO- Oliver Schlüter: Chief Financial OfficerPast Role: CureVac, Chief Financial Officer
About the Company
Betaliq is a collaboration between Novaliq, GMBH, and BLP Management Group, LLC. It was formed to develop ophthalmic beta-blockers using Novaliq’s patented EyeSol non-water formulation technology.
The company is developing two beta-blockers, for the treatment of glaucoma. BTQ 1901 is an EyeSol based formulation of a potent selective beta-blocker
that has not previously been used to treat glaucoma. BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta-blockers.
